Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles

Biomaterials

Volumn 27, Issue 33, 2006, Pages 5725-5733

  Hu, F X ^a   Neoh, K G ^a   Kang, E T ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Composite nanoparticles; Controlled release; Magnetic drug targeting; MRI; Tamoxifen

Indexed keywords

COMPOSITE NANOPARTICLES; CONTROLLED RELEASE; MAGNETIC DRUG TARGETING; TAMOXIFEN;

BIOASSAY; COMPOSITE MATERIALS; ENCAPSULATION; MAGNETITE; PARAMAGNETISM; SYNTHESIS (CHEMICAL); TOXICITY; TUMORS;

NANOSTRUCTURED MATERIALS;

DRUG CARRIER; IRON; MAGNETITE; NANOPARTICLE; ORGANIC MATTER; POLYLACTIC ACID; SOLVENT; SUPERPARAMAGNETIC IRON OXIDE; TAMOXIFEN; WATER OIL CREAM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CELL STRUCTURE; COMPOSITE MATERIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; EVAPORATION; EXTRACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INTRACELLULAR SPACE; MAGNETISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SHAPE; DRUG CARRIERS; ESTROGEN ANTAGONISTS; FERROSOFERRIC OXIDE; HUMANS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYMERS; TAMOXIFEN;

EID: 33748091709     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2006.07.014     Document Type: Article

References (45)

1. O'Regan R.M., and Jordan V.C. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3 (2002) 207-214
2. Bonneterre J., Thurlimann B., Robertson J.F.R., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18 (2000) 3748-3757
3. Cameron D.A., Ritchie A.A., Langdon S., Anderson T.J., and Miller W.R. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat 45 (1997) 99-107
4. Osborne C.K. Drug therapy-Tamoxifen in the treatment of breast cancer. N Engl J Med 339 (1998) 1609-1618
5. Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pugh R.P., et al. Prognostic-significance of progesterone-receptor levels in estrogen receptor-positive patients with metastatic breast-cancer treated with tamoxifen-results of a prospective Southwest-Oncology-Group Study. J Clin Oncol 10 (1992) 1284-1291
6. de Lima G.R., Facina G., Shida J.Y., Chein M.B.C., Tanaka P., Dardes R.C., et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 39 (2003) 891-898
7. Peyrade F., Frenay M., Etienne M.C., Ruch F., Guillemare C., Francois E., et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59 (1996) 401-410
8. Clarke M., Collins R., Davies C., Godwin J., Gray R., and Peto R. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
9. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., and Wilking N. Adjuvant tamoxifen therapy for early-stage breast-cancer and 2nd primary malignancies. J Natl Cancer Inst 87 (1995) 645-651
10. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90 (1998) 1371-1388
11. Kisanga E.R., Gjerde J., Guerrieri-Gonzaga A., Pigatto F., Pesci-Feltri A., Robertson C., et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10 (2004) 2336-2343
12. Voltairas P.A., Fotiadis D.I., and Michalis L.K. Hydrodynamics of magnetic drug targeting. J Biomech 35 (2002) 813-821
13. Lubbe A.S., Bergemann C., Riess H., Schriever F., Reichardt P., Possinger K., et al. Clinical experiences with magnetic drag targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56 (1996) 4686-4693
14. Lubbe A.S., Alexiou C., and Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res 95 (2001) 200-206
15. Lubbe A.S., Bergemann C., Huhnt W., Fricke T., Riess H., Brock J.W., et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56 (1996) 4694-4701
16. Alexiou C., Jurgons R., Schmid R.J., Bergemann C., Henke J., Erhardt W., et al. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11 (2003) 139-149
17. Rudge S., Peterson C., Vessely C., Koda J., Stevens S., and Catterall L. Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC). J Control Release 74 (2001) 335-340
18. Rudge S.R., Kurtz T.L., Vessely C.R., Catterall L.G., and Williamson D.L. Preparation, characterization, and performance of magnetic iron-carbon composite microparticles for chemotherapy. Biomaterials 21 (2000) 1411-1420
19. Fricker J. Drugs with a magnetic attraction to tumours. Drug Discov Today 6 (2001) 387-389
20. Zheng W.M., Gao F., and Gu H.C. Magnetic polymer nanospheres with high and uniform magnetite content. J Magn Magn Mater 288 (2005) 403-410
21. Arias J.L., Gallardo V., Gomez-Lopera S.A., Plaza R.C., and Delgado A.V. Synthesis and characterization of poly (ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release 77 (2001) 309-321
22. Gomez-Lopera S.A., Arias J.L., Gallardo V., and Delgado A.V. Colloidal stability of magnetite/poly(lactic acid) core/shell nanoparticles. Langmuir 22 (2006) 2816-2821
23. Okassa L.N., Marchais H., Douziech-Eyrolles L., Cohen-Jonathan S., Souce M., Dubois P., et al. Development and characterization of sub-micron poly(d,l-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. Int J Pharm 302 (2005) 187-196
24. Asmatulu R., Zalich M.A., Claus R.O., and Riffle J.S. Synthesis, characterization and targeting of biodegradable magnetic nanocomposite particles by external magnetic fields. J Magn Magn Mater 292 (2005) 108-119
25. Iannone A., Magin R.L., Walczak T., Federico M., Swartz H.M., Tomasi A., et al. Blood clearance of dextran magnetite particles determined by a noninvasive invivo ESR method. Magn Reson Med 22 (1991) 435-442
26. Muller R.H., Maaen S., Weyhers H., Specht F., and Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 138 (1996) 85-94
27. Tiefenauer L.X., Tschirky A., Kuhne G., and Andres R.Y. In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn Reson Imag 14 (1996) 391-402
28. Choi H., Choi S.R., Zhou R., Kung H.F., and Chen I.W. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 11 (2004) 996-1004
29. Chawla J.S., and Amiji M.M. Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 249 (2002) 127-138
30. Chawla J.S., and Amiji M.M. Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles. AAPS Pharmsci 5 (2003) 1-7
31. Cavallaro G., Maniscalco L., Licciardi M., and Giammona G. Tamoxifen-loaded polymeric micelles: preparation, physico-chemical characterization and in vitro evaluation studies. Macromol Biosci 4 (2004) 1028-1038
32. Fontana G., Maniscalco L., Schillaci D., Cavallaro G., and Giammona G. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv 12 (2005) 385-392
33. Memisoglu-Bilensoy E., Vural L., Bochot A., Renoir J.M., Duchene D., and Hincal A.A. Tarnoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J Control Release 104 (2005) 489-496
34. 4 (M=Fe, Co, Mn) nanoparticles. J Am Chem Soc 126 (2004) 273-279
35. Hu F.X., Neoh K.G., Cen L., and Kang E.T. Cellular response to magnetic nanoparticles "PEGylated" via surface-initiated atom transfer radical polymerization. Biomacromolecules 7 (2006) 809-816
36. Okon E., Pouliquen D., Okon P., Kovaleva Z.V., Stepanova T.P., Lavit S.G., et al. Biodegradation of magnetite dextran nanoparticles in the rat-a histologic and biophysical study. Lab Invest 71 (1994) 895-903
37. Kuperman V. Magnetic resonance imaging: physical principles and applications (2000), Academic Press, San Diego
38. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000) 271-284
39. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59 (1999) 4129-4135
40. Nomura T., Koreeda N., Yamashita F., Takakura Y., and Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res 15 (1998) 128-132
41. Maillard S., Ameller T., Gauduchon J., Gougelet A., Gouilleux F., Legrand P., et al. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol 94 (2005) 111-121
42. Shenoy D.B., and Amiji M.A. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 293 (2005) 261-270
43. Moulder JF, Stickle WF, Sobol PE, Bomben K. Handbook of X-ray photoelectron spectroscopy. Chastain J. Eden Prairie: Perkin-Elmer Corporation; 1992.
44. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 50 (1998) 31-40
45. Sahoo S.K., Panyam J., Prabha S., and Labhasetwar V. Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82 (2002) 105-114